Valerie D Myers1, Glenn S Gerhard2, Dennis M McNamara3, Dhanendra Tomar4, Muniswamy Madesh5, Scott Kaniper2, Frederick V Ramsey4, Susan G Fisher4, Roxann G Ingersoll6, Laura Kasch-Semenza6, JuFang Wang5, Karen Hanley-Yanez3, Bonnie Lemster3, Jessica A Schwisow7, Amrut V Ambardekar7, Seta H Degann7, Michael R Bristow7, Richard Sheppard8, Jeffrey D Alexis9, Douglas G Tilley5, Christopher D Kontos10, Joseph M McClung11, Anne L Taylor12, Clyde W Yancy13,14, Kamel Khalili15, Jonathan G Seidman16, Christine E Seidman16,17,18, Charles F McTiernan3, Joseph Y Cheung5, Arthur M Feldman1. 1. Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania. 2. Department of Human Genetics and Molecular Biochemistry, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania. 3. The Heart and Vascular Institute, the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 4. Department of Clinical Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania. 5. The Center for Translational Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania. 6. The McKusick-Nathans Institute for Genetic Medicine, the Johns Hopkins University School of Medicine, Baltimore, Maryland. 7. Department of Medicine, University of Colorado School of Medicine, Denver. 8. Department of Medicine, McGill University and the Jewish General Hospital, Montreal, Quebec, Canada. 9. Department of Medicine, the University of Rochester, Rochester, New York. 10. Division of Cardiology, Department of Medicine and the Department of Pharmacology and Cancer, Duke University School of Medicine, Durham, North Carolina. 11. Department of Physiology and Cardiovascular Sciences, East Carolina Diabetes and Obesity Institute, Brody School of Medicine, Greenville, North Carolina. 12. Division of Cardiology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York. 13. Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 14. Deputy Editor. 15. Department of Neuroscience, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania. 16. Department of Genetics, Harvard Medical School, Boston, Massachusetts. 17. Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 18. The Howard Hughes Medical Institute, Chevy Chase, Maryland.
Abstract
Importance: The prevalence of nonischemic dilated cardiomyopathy (DCM) is greater in individuals of African ancestry than in individuals of European ancestry. However, little is known about whether the difference in prevalence or outcomes is associated with functional genetic variants. Objective: We hypothesized that Bcl2-associated anthanogene 3 (BAG3) genetic variants were associated with outcomes in individuals of African ancestry with DCM. Design: This multicohort study of the BAG3 genotype in patients of African ancestry with dilated cardiomyopathy uses DNA obtained from African American individuals enrolled in 3 clinical studies: the Genetic Risk Assessment of African Americans With Heart Failure (GRAHF) study; the Intervention in Myocarditis and Acute Cardiomyopathy Trial-2 (IMAC-2) study; and the Genetic Risk Assessment of Cardiac Events (GRACE) study. Samples of DNA were also acquired from the left ventricular myocardium of patients of African ancestry who underwent heart transplant at the University of Colorado and University of Pittsburgh. Main Outcomes and Measures: The primary end points were the prevalence of BAG3 mutations in African American individuals and event-free survival in participants harboring functional BAG3 mutations. Results: Four BAG3 genetic variants were identified; these were expressed in 42 of 402 African American individuals (10.4%) with nonischemic heart failure and 9 of 107 African American individuals (8.4%) with ischemic heart failure but were not present in a reference population of European ancestry (P < .001). The variants included 2 nonsynonymous single-nucleotide variants; 1 three-nucleotide in-frame insertion; and 2 single-nucleotide variants that were linked in cis. The presence of BAG3 variants was associated with a nearly 2-fold (hazard ratio, 1.97 [95% CI, 1.19-3.24]; P = .01) increase in cardiac events in carriers compared with noncarriers. Transfection of transformed adult human ventricular myocytes with plasmids expressing the 4 variants demonstrated that each variant caused an increase in apoptosis and a decrease in autophagy when samples were subjected to the stress of hypoxia-reoxygenation. Conclusions and Relevance: This study demonstrates that genetic variants in BAG3 found almost exclusively in individuals of African ancestry were not causative of disease but were associated with a negative outcome in patients with a dilated cardiomyopathy through modulation of the function of BAG3. The results emphasize the importance of biological differences in causing phenotypic variance across diverse patient populations, the need to include diverse populations in genetic cohorts, and the importance of determining the pathogenicity of genetic variants.
Importance: The prevalence of nonischemic dilated cardiomyopathy (DCM) is greater in individuals of African ancestry than in individuals of European ancestry. However, little is known about whether the difference in prevalence or outcomes is associated with functional genetic variants. Objective: We hypothesized that Bcl2-associated anthanogene 3 (BAG3) genetic variants were associated with outcomes in individuals of African ancestry with DCM. Design: This multicohort study of the BAG3 genotype in patients of African ancestry with dilated cardiomyopathy uses DNA obtained from African American individuals enrolled in 3 clinical studies: the Genetic Risk Assessment of African Americans With Heart Failure (GRAHF) study; the Intervention in Myocarditis and Acute Cardiomyopathy Trial-2 (IMAC-2) study; and the Genetic Risk Assessment of Cardiac Events (GRACE) study. Samples of DNA were also acquired from the left ventricular myocardium of patients of African ancestry who underwent heart transplant at the University of Colorado and University of Pittsburgh. Main Outcomes and Measures: The primary end points were the prevalence of BAG3 mutations in African American individuals and event-free survival in participants harboring functional BAG3 mutations. Results: Four BAG3 genetic variants were identified; these were expressed in 42 of 402 African American individuals (10.4%) with nonischemic heart failure and 9 of 107 African American individuals (8.4%) with ischemic heart failure but were not present in a reference population of European ancestry (P < .001). The variants included 2 nonsynonymous single-nucleotide variants; 1 three-nucleotide in-frame insertion; and 2 single-nucleotide variants that were linked in cis. The presence of BAG3 variants was associated with a nearly 2-fold (hazard ratio, 1.97 [95% CI, 1.19-3.24]; P = .01) increase in cardiac events in carriers compared with noncarriers. Transfection of transformed adult human ventricular myocytes with plasmids expressing the 4 variants demonstrated that each variant caused an increase in apoptosis and a decrease in autophagy when samples were subjected to the stress of hypoxia-reoxygenation. Conclusions and Relevance: This study demonstrates that genetic variants in BAG3 found almost exclusively in individuals of African ancestry were not causative of disease but were associated with a negative outcome in patients with a dilated cardiomyopathy through modulation of the function of BAG3. The results emphasize the importance of biological differences in causing phenotypic variance across diverse patient populations, the need to include diverse populations in genetic cohorts, and the importance of determining the pathogenicity of genetic variants.
Authors: Nadine Norton; Duanxiang Li; Mark J Rieder; Jill D Siegfried; Evadnie Rampersaud; Stephan Züchner; Steve Mangos; Jorge Gonzalez-Quintana; Libin Wang; Sean McGee; Jochen Reiser; Eden Martin; Deborah A Nickerson; Ray E Hershberger Journal: Am J Hum Genet Date: 2011-02-25 Impact factor: 11.025
Authors: D M McNamara; R Holubkov; R C Starling; G W Dec; E Loh; G Torre-Amione; A Gass; K Janosko; T Tokarczyk; P Kessler; D L Mann; A M Feldman Journal: Circulation Date: 2001-05-08 Impact factor: 29.690
Authors: Hossein Bahrami; Richard Kronmal; David A Bluemke; Jean Olson; Steven Shea; Kiang Liu; Gregory L Burke; João A C Lima Journal: Arch Intern Med Date: 2008-10-27
Authors: Dennis M McNamara; S William Tam; Michael L Sabolinski; Page Tobelmann; Karen Janosko; Lakshmi Venkitachalam; Elizabeth Ofili; Clyde Yancy; Arthur M Feldman; Jalal K Ghali; Anne L Taylor; Jay N Cohn; Manuel Worcel Journal: J Card Fail Date: 2008-12-23 Impact factor: 5.712
Authors: Mercedes R Carnethon; Jia Pu; George Howard; Michelle A Albert; Cheryl A M Anderson; Alain G Bertoni; Mahasin S Mujahid; Latha Palaniappan; Herman A Taylor; Monte Willis; Clyde W Yancy Journal: Circulation Date: 2017-10-23 Impact factor: 29.690
Authors: Joseph Yeboah; Carlos J Rodriguez; Brandon Stacey; Joao A Lima; Songtao Liu; J Jeffrey Carr; W Gregory Hundley; David M Herrington Journal: Circulation Date: 2012-11-02 Impact factor: 29.690
Authors: Melissa J Landrum; Jennifer M Lee; George R Riley; Wonhee Jang; Wendy S Rubinstein; Deanna M Church; Donna R Maglott Journal: Nucleic Acids Res Date: 2013-11-14 Impact factor: 16.971
Authors: Thomas G Martin; Sara Tawfik; Christine S Moravec; Toni R Pak; Jonathan A Kirk Journal: Am J Physiol Heart Circ Physiol Date: 2021-05-14 Impact factor: 5.125
Authors: Arthur M Feldman; Jennifer Gordon; Jufang Wang; Jianliang Song; Xue-Qian Zhang; Valerie D Myers; Dhanendra Tomar; Glenn S Gerhard; Kamel Khalili; Joseph Y Cheung Journal: J Card Fail Date: 2020-09-18 Impact factor: 5.712